Latest vCJD (Creutzfeldt-Jakob disease) precautions in UK highlight diagnostics need
This article was originally published in Clinica
The need for an in vivo diagnostic for variant Creutzfeldt-Jakob disease (vCJD) was brought to the fore again last week, when the UK DoH (Department of Health) extended its precautionary measures to reduce the risk of transmission through blood transfusion and surgical procedures.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.